This big biotech stock doesn't get the hype that SpaceX does. But it could be the smarter bet right now.

One firm sees room for this tech stock to run.

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved an expanded label for Vertex Pharmaceuticals Incorporated‘s ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

VRTX gets FDA approval to expand Casgevy use in patients aged two and older with SCD or TDT, a first for genetic therapies in ...

After emerging from bankruptcy last year, Vertex Energy is making another change to its Alabama refinery, which the Houston ...